- Home
- ALPS vs PRQR Comparison
ALPS vs PRQR Comparison
Compare ALPS & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALPS | PRQR |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | Malaysia | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 163.3M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALPS | PRQR |
|---|---|---|
| Price | $0.98 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 34.0K | ★ 334.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.08 |
| 52 Week High | $1.72 | $3.10 |
Technical Indicators
Market Signals| Indicator | ALPS | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 51.21 |
| Support Level | $0.87 | $1.33 |
| Resistance Level | $1.02 | $2.27 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 46.15 | 74.29 |
Price Performance
Historical ComparisonAbout ALPS ALPS Group Inc Ordinary Share
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.